Ovarian Cancer Awareness Month: Studies show advances in treatment, symptom management
Click Here to Manage Email Alerts
September is Ovarian Cancer Awareness Month.
Ovarian cancer is the fifth most common cause of cancer death among women, according to American Cancer Society.
Approximately 19,880 women in the United States will be diagnosed with ovarian cancer this year and an estimated 12,810 will die of the disease, according to society statistics.
In conjunction with Ovarian Cancer Awareness Month, Healio presents the following important updates in treatment and research.
1. Maintenance therapy with olaparib (Lynparza; AstraZeneca, Merck) and bevacizumab (Avastin, Genentech) extended survival for women with newly diagnosed advanced ovarian cancer with homologous recombination deficiency. Read more.
2. A phase 3 trial of ofranergene obadenovec (VB-111, VBL Therapeutics) in platinum-resistant ovarian cancer failed to meet its primary endpoints of PFS and OS. Read more.
3. Researchers developed and evaluated nurse-led and self-administered versions of a symptom management tool to assess its impact on symptoms among women with ovarian cancer. Read more.
4. The addition of intermittent relacorilant (Corcept Therapeutics) plus nab-paclitaxel (Abraxane, Bristol Myers Squibb) extended OS for women with recurrent platinum-resistant/refractory ovarian cancer. Read more.
5. Rucaparib (Rubraca, Clovis Oncology) significantly prolonged PFS compared with placebo in the first-line maintenance setting among women with advanced ovarian cancer. Read more.
6. Women who take aspirin frequently may reduce their risk for ovarian cancer. Read more.
7. The FDA granted fast track designation to ofranergene obadenovec (VB-111, VBL Therapeutics) in combination with paclitaxel for treatment of platinum-resistant ovarian cancer. Read more.
8. Women with mitogen-activated protein kinase-mutated low-grade serous ovarian/peritoneal carcinoma achieved significantly longer PFS and OS than women without these mutations. Read more.
9. Folate receptor alpha expression predicted benefit from mirvetuximab soravtansine (IMGN853, ImmunoGen) in platinum-resistant high-grade serous epithelial ovarian, primary peritoneal or fallopian tube cancers. Read more.
10. A trained artificial intelligence model predicted treatment outcomes before surgery of women with high-grade serous ovarian cancer. Read more.
Reference:
- American Cancer Society. Key statistics for ovarian cancer. www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html. Accessed Sept. 15, 2022.
Collapse
Healio Coverage
Click Here to Manage Email Alerts